Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
294 participants
INTERVENTIONAL
2017-07-12
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Implementation intervention
Implementation intervention
The implementation intervention includes peer-to-peer training, post-training outreach, proactive expert support, and assistance with addressing environmental barriers.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Implementation intervention
The implementation intervention includes peer-to-peer training, post-training outreach, proactive expert support, and assistance with addressing environmental barriers.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Receive Ryan White Funding;
* Treat adults with HIV;
* Have 3 or more prescribing clinicians;
* Have an electronic medical record (EMR) with an electronic medication list.
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
The Miriam Hospital
OTHER
Boston Medical Center
OTHER
Rhode Island Hospital
OTHER
Baystate Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Peter Friedmann
Chief Research Officer and Endowed Chair for Clinical Research
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter D Friedmann, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
University of Massachusetts Medical School - Baystate
Josiah D Rich, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
The Miriam Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Massachusetts Medical School - Baystate
Springfield, Massachusetts, United States
The Miriam Hospital
Providence, Rhode Island, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Jawa R, Walley AY, Wilson DJ, Green TC, McKenzie M, Hoskinson R Jr, Bratberg J, Ramsey S, Rich JD, Friedmann PD. Prescribe to Save Lives: Improving Buprenorphine Prescribing Among HIV Clinicians. J Acquir Immune Defic Syndr. 2022 Aug 15;90(5):546-552. doi: 10.1097/QAI.0000000000003001.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BH-15-259
Identifier Type: -
Identifier Source: org_study_id